Active Substance: Erythromycin (as ethylsuccinate).
Overview
Welcome to Dwaey, specifically on ERYTHRODAR 250mg page.
This medicine contains an important and useful components, as it consists of
Erythromycin (as ethylsuccinate)is available in the market in concentration
Erythromycin
Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. Lactation: distributed in breast milk, use with caution; AAP categorizes as compatible with breastfeeding
Susceptible infections, Respiratory tract infections, Enteritis, Pertussis, Trench fever, Chanroid, Chlamydial infections, Diphtheria, Legionnaire's disease, Pneumonia, Sinusitis, Bronchitis, Acne, Rheumatic fever, Neonatal conjunctivitis.
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
1-10% Abdominal pain (8%),Headache (8%),Nausea (8%),Diarrhea (7%),Rash (3%),Vomiting (3%),Dyspepsia (2%),Flatulence (2%),Pain (2%),Pruritus (1%),Pseudomembranous colitis Hypertrophic pyloric stenosis,Anaphylaxis,Fever,Mild allergic reactions,Urticaria,Skin eruptions,Tinnitus <1% Cholestatic hepatitis,Confusion,Hallucinations,Hearing loss,Hypotension,Nervous system effects including seizures,Torsade de pointes,Ventricular tachycardia,Vertigo Potentially Fatal: Hepatotoxicity, cholestatic jaundice; raised serum transaminases; eosinophilia.
2
Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.
May decrease plasma levels of valproic acid thus, increasing the risk of seizures. Increased plasma concentrations w/ probenecid.
Information not available